ON
Oleg Nodelman (Director) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in Zymeworks Inc. (ZYME). Across 2 priced purchase filings, the average 21-session return was +0.2% from execution and -3.7% from disclosure (delay-adjusted; derived). The largest single filing was $13.1M of ZYME (1,081,980 sh across 3 lots, as filed), executed Mar 11 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+0.2%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-3.7%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$16.7M
shares × price, as filed
Last traded
Apr 4 2025
Filed Apr 7 2025
Median ADV $18.1M across their filed names
Open performance→Volume by month
Buys $16.7M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
ZYME
Zymeworks Inc.
ZYME · 2 buys · 0 sells
2 filings
Recent filings
ZYMEPURCHASE
Zymeworks Inc.
View filing →
$3.6M317,208 sh across 2 lots
Exec Apr 3 2025
Filed Apr 7 2025 · 5:30 PM ET ZYMEPURCHASE Zymeworks Inc. View filing → $13.1M
1,081,980 sh across 3 lots
Exec Mar 11 2025
Filed Mar 13 2025 · 5:30 PM ET